Publications Positive Review of Veyonda in Chemotherapy
Filed with ASX · · 4 pages · English
Story so far
Earlier from Noxopharm
- Clinical Data Shows Noxopharm’s Veyonda® May Prevent Cytokine Storm
- March Quarterly Activities Report and Appendix 4C
- Veyonda Showing Potential to Prevent Cytokine Storm
- Noxopharm Files Septic Shock Treatment Patent for Veyonda®
- Veyonda Patent Lodged for Major Septic Shock Opportunity
Later from Noxopharm
- Veyonda FDA Approved Trial to Commence
- Veyonda to Begin First-Line Sarcoma Treatment Testing
- New Independent Trial Data Supports Potential of Veyonda
- Noxopharm Set to Benefit From Novartis ASCO Data
- DARRT-2 Study Update and Clarification
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm